MELBOURNE, Australia, June 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present details of its FMS drug discovery and development program at the Protein Kinase Targets conference, a leading conference for breakthrough scientific data on new kinase inhibitory drugs. This conference will be held from 23 to 25 June in Boston, USA.
This is the first scientific disclosure of data from the Cytopia FMS program and will be presented by Cytopia Senior Scientist Dr Michael Harte. Dr Harte's presentation is scheduled for 3:15 pm (US EDT) 25 June.
The presentation will describe the potent activity of a series of compounds discovered at Cytopia. These compounds inhibit the function of macrophages, key cells in the immune system and mediators of inflammatory reactions. As such these compounds have therapeutic potential in treating conditions such as rheumatoid arthritis. The inhibition of cells that are responsible for bone osteolysis in advanced cancer disease is also part of the physiological potential of FMS inhibitors.
Preliminary data on the potential of Cytopia's potent FMS inhibitors to treat advanced cancer in in vivo models will also be presented at this conference.
Cytopia CEO Mr Andrew Macdonald said, "We are very encouraged by the excellent preclinical profile of these compounds. This first public disclosure of our work raises the profile of this program to the broader scientific community and reflects the excellent science undertaken by the team."
This presentation is in the same month that Cytopia presented its CYT997 cancer findings to ASCO, the world's biggest oncology conference held in Chicago.
Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer. Cytopia's lead compound, CYT997, is currently in Phase II clinical trials.
|SOURCE Cytopia Limited|
Copyright©2008 PR Newswire.
All rights reserved